This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Drugs for Neglected Diseases initiative

Drug Names(s): E-1224, ravuconazole prodrug

Description: E1224 is a prodrug which converts to the active drug ravuconazole. Ravuconazole acts by inhibiting cytochrome P450 14a-demethylase (P45014DM) present in the sterol biosynthesis pathway.

Deal Structure: Eisai and DNDi
In September 2009, Eisai and the Drugs for Neglected Diseases initiative (DNDi) announced that they have signed a collaboration and license agreement for the clinical development for the treatment of Chagas disease. Under the terms of the agreement, DNDi shall retain sole responsibility for the clinical development to assess the safety and efficacy of E1224, which is a pro-drug of ravuconazole, in patients with Chagas disease within endemic countries. Eisai shall provide DNDi guidance on the clinical development as well as supply the drug for the clinical studies. Eisai shall also have the option to become the industrial partner with DNDi to manufacture, register and make available E1224 at an affordable price to the public sector in endemic countries.

Partners: Eisai Co., Ltd.

E1224 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug